What is GxP?
GxP is the umbrella term for the "good practice" regulations and guidelines that govern regulated life sciences work, including good manufacturing, laboratory, clinical, distribution, and documentation practice. The x stands in for the specific discipline. Together they require that products are safe, effective, and of known quality, and that the records proving it can be trusted.
Also known as Good practice regulations · Good x practice
What the x in GxP stands for
The G stands for good and the P for practice; the x is a placeholder for the discipline in question. GMP is good manufacturing practice, GLP is good laboratory practice, GCP is good clinical practice, and so on. Referring to them collectively as GxP is shorthand for "whichever good practice rules apply to this activity."
The individual GxPs differ in scope, but they share a common set of expectations:
- Written, approved procedures for work that affects product quality, patient safety, or data used in regulatory decisions.
- Qualified people who are trained on those procedures, with training documented.
- Controlled materials, equipment, and facilities — qualified, calibrated, maintained, and traceable.
- Records that prove what happened, created at the time of the work and kept for a defined retention period.
- Independent quality oversight, usually a quality unit with authority to approve or reject.
- A way to handle things going wrong: deviations, investigations, and corrective and preventive action.
Some GxPs are binding regulations — the U.S. current good manufacturing practice rules, for example, are codified in the Code of Federal Regulations. Others are guidelines, such as those published by the International Council for Harmonisation (ICH), that regulators adopt and expect companies to follow. In practice, inspectors treat both as the standard you will be held to.
The main GxPs
The disciplines below are the ones most life sciences organizations deal with. Which apply to you depends on what you make, test, or study, and where you sell it.
| Practice | What it governs | Key references |
|---|---|---|
| GMP — good manufacturing practice | Manufacturing, testing, packaging, and release of medicines, including active ingredients | 21 CFR Parts 210 and 211 (U.S. drugs); EudraLex Volume 4 (EU); ICH Q7 (active pharmaceutical ingredients) |
| GLP — good laboratory practice | Nonclinical safety studies whose data supports applications to regulators | 21 CFR Part 58 (U.S.); OECD Principles of GLP |
| GCP — good clinical practice | Design, conduct, recording, and reporting of clinical trials in human subjects | ICH E6; 21 CFR Parts 50, 56, and 312 (U.S.) |
| GDP — good distribution practice | Storage, transport, and handling of medicines through the supply chain | EU Guidelines on Good Distribution Practice of medicinal products for human use |
| GDocP — good documentation practice | How records are created, corrected, reviewed, and retained across every GxP | Embedded in each GxP; expanded on in regulators' data integrity guidance |
| GVP — good pharmacovigilance practice | Monitoring and reporting the safety of medicines once they are on the market | EMA's GVP modules (EU) |
Two naming collisions are worth knowing about. "GDP" is sometimes used for good documentation practice rather than distribution practice, so check which one a document means. And medical devices follow their own quality system rules — in the U.S., 21 CFR Part 820, which FDA has amended to align with the ISO 13485 standard — rather than drug GMP, although the principles overlap heavily.
Who sets and enforces GxP
- FDA (United States) writes and enforces the GxP regulations in Title 21 of the CFR. Inspection findings are issued on Form 483; serious or unresolved problems can lead to warning letters, import alerts, or consent decrees.
- EMA and national competent authorities (European Union) — the EMA coordinates, while member-state inspectorates carry out most inspections.
- MHRA (United Kingdom) inspects and enforces GxP for medicines and has published influential guidance on data integrity.
- PIC/S, the Pharmaceutical Inspection Co-operation Scheme, harmonizes GMP inspection practice among its member authorities.
- ICH brings regulators and industry together to publish harmonized guidelines, including the quality (Q) and efficacy (E) series.
- WHO publishes GMP guidance that many national regulatory systems build on, and the OECD maintains the GLP principles behind the mutual acceptance of nonclinical data.
GxP and computerized systems
Any software that creates, processes, stores, or reports GxP data — or controls a GxP process — is a GxP system. That covers obvious candidates such as LIMS, ELNs, and manufacturing execution systems, and less obvious ones such as instrument software, spreadsheets used for calculations, and cloud platforms holding regulated records.
GxP systems have to be validated for their intended use: there must be documented evidence that the system does what it is supposed to do, reliably, in your environment. In the U.S., electronic records and signatures in those systems also fall under 21 CFR Part 11; in the EU, Annex 11 of the GMP guidelines covers computerised systems.
Industry practice for validation is shaped by ISPE's GAMP 5 guide, now in its second edition, which promotes a risk-based approach: scale the rigor of specification and testing to the system's impact on patient safety, product quality, and data integrity, and lean on supplier documentation where it is trustworthy. FDA's computer software assurance guidance, written for medical device production and quality system software, pushes in the same direction — less paperwork for its own sake, more critical thinking about what could actually go wrong.
A typical lifecycle for a GxP system includes:
- An assessment of whether, and how much, the system affects GxP data or processes.
- Documented requirements for its intended use.
- Supplier assessment, scaled to risk.
- Risk-based configuration, testing, and traceability back to requirements.
- Release under change control, with procedures and training in place.
- Periodic review, incident handling, and eventually controlled retirement with data preserved.
Data integrity: the thread through every GxP
Every GxP depends on records, because records are the evidence that the work was done correctly. That is why data integrity has become a central focus of inspections across manufacturing, laboratories, and clinical research. Regulators describe what trustworthy data looks like with the ALCOA+ principles: attributable, legible, contemporaneous, original, and accurate, as well as complete, consistent, enduring, and available.
When a record falls short — a missing signature, a result transcribed hours later, an unexplained repeat test — the problem usually surfaces as a deviation that has to be investigated. Many of the hardest investigations are hard precisely because the hands-on work was never captured in enough detail to reconstruct what happened.
What GxP means for software buyers and vendors
There is no such thing as GxP-certified software. Regulators don't certify products; the regulated company is responsible for validating and controlling every system it uses. A vendor can make that much easier, or much harder. The following questions are a practical starting point for evaluating a system for GxP use — they are not legal or regulatory advice:
- Does the vendor operate its own quality management system, and will it support supplier audits or questionnaires?
- What validation documentation is available — requirements, design, test evidence, release notes — and how can you leverage it?
- How are changes communicated, and can you control when updates reach your validated environment?
- Does the system provide unique user accounts, role-based access, audit trails, and electronic signatures that meet your requirements?
- Can you export complete records, with their metadata and audit trails, in a readable form for the full retention period?
- Where is data stored and backed up, and is on-premises or isolated deployment available if your policies require it?
Where QURE fits
QURE Science is built for GxP laboratories. It delivers AI-guided protocol execution with in-line deviation detection and captures governed data directly from instruments and operator actions as the work happens, designed to support GxP record-keeping. It integrates with ELN, LIMS, and robotics platforms, and can be deployed in the cloud, on-premises, or air-gapped. As with any GxP system, validation for your intended use remains your organization's responsibility; QURE's role is to make the execution record complete and contemporaneous to begin with.
Frequently asked questions
What does GxP stand for?
GxP stands for "good x practice," where the x is replaced by the relevant discipline: manufacturing (GMP), laboratory (GLP), clinical (GCP), distribution (GDP), documentation (GDocP), pharmacovigilance (GVP), and others. It is a collective term for the quality regulations and guidelines that govern regulated life sciences work.
Is GxP a law?
Partly. Some GxPs are binding regulations, such as the U.S. current good manufacturing practice rules in 21 CFR Parts 210 and 211 and the GLP rules in Part 58. In the EU, GMP principles are set out in legislation and detailed in the EudraLex Volume 4 guidelines. Other GxP documents, such as ICH guidelines, are guidance that regulators adopt and expect companies to follow.
What is the difference between GMP and cGMP?
The c stands for current. FDA uses the term current good manufacturing practice to signal that manufacturers are expected to use up-to-date technologies, systems, and methods, not just the minimum that was acceptable when the rules were written. In everyday use the two terms refer to the same body of requirements.
Does GxP apply to software and cloud services?
Yes, whenever the software creates, stores, processes, or reports GxP data, or controls a GxP process. The regulated company must validate the system for its intended use and maintain control over it, including when it is hosted by a third party. Supplier assessments and quality agreements are how that control extends to vendors.
Sources
- 21 CFR Part 211 — Current Good Manufacturing Practice for Finished Pharmaceuticals (eCFR)
- 21 CFR Part 58 — Good Laboratory Practice for Nonclinical Laboratory Studies (eCFR)
- ICH quality guidelines (including Q7, Q9, and Q10)
- ISPE GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (second edition)
Related terms: 21 CFR Part 11, ALCOA+, Deviation management, Lab reproducibility. Browse the full glossary, read field notes in the QURE Journal, or request a demo to see execution intelligence on your own procedures.